Evaxion A/S (EVAX) to Post Earnings on Thursday

Evaxion A/S (NASDAQ:EVAX) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.01) per share and revenue of $6.70 million for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.

Evaxion A/S Stock Down 1.6%

Evaxion A/S stock opened at $3.05 on Tuesday. The firm has a market capitalization of $25.44 million, a PE ratio of -2.07 and a beta of 0.29. The company’s 50-day moving average is $3.22 and its 200-day moving average is $3.59. Evaxion A/S has a fifty-two week low of $2.52 and a fifty-two week high of $12.15. The company has a debt-to-equity ratio of 0.41, a current ratio of 5.85 and a quick ratio of 5.85.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Weiss Ratings upgraded Evaxion A/S from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. HC Wainwright restated a “buy” rating and issued a $16.00 price objective on shares of Evaxion A/S in a research note on Friday, April 24th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Trading of Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. SmartHarvest Portfolios LLC acquired a new stake in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 15,194 shares of the company’s stock, valued at approximately $72,000. SmartHarvest Portfolios LLC owned approximately 0.18% of Evaxion A/S at the end of the most recent reporting period. Institutional investors own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.